Which of the following is a JAK inhibitor used for immune-mediated diseases?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards

From $24.99Unlock all

Prepare for the Dermatology Week 1 Exam with comprehensive study materials. Practice with detailed questions, flashcards, and expert explanations. Boost your knowledge and confidence for the exam!

Multiple Choice

Which of the following is a JAK inhibitor used for immune-mediated diseases?

Janus kinase (JAK) inhibitors block JAK-STAT signaling, which is how many cytokines convey inflammatory messages in autoimmune diseases. Tofacitinib is a small-molecule JAK inhibitor that mainly targets JAK1 and JAK3, dampening signals from cytokines like IL-2, IL-4, IL-6, and IFN-γ. This makes it effective for conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. The other drugs listed are not JAK inhibitors: Rituximab depletes B cells by targeting CD20; Abatacept inhibits T-cell activation by blocking CD28 costimulation; Adalimumab neutralizes TNF-α. So the JAK inhibitor used for immune-mediated diseases is Tofacitinib.

Which of the following is a JAK inhibitor used for immune-mediated diseases?

Prepare for the Dermatology Week 1 Exam with comprehensive study materials. Practice with detailed questions, flashcards, and expert explanations. Boost your knowledge and confidence for the exam!

Which of the following is a JAK inhibitor used for immune-mediated diseases?

Get the latest from Examzify